A Phase 3 interventional study of Epoetin Alfa and Roxadustat in CKD Anemia in Stable Dialysis Patients, sponsored by FibroGen. Completed at 76 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by FibroGen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.
Among the 43 studies testing roxadustat in Anemia, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 25 in phase 3, and was the 15th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:
Kyntra Bio
Ages 18+
Tianjin Medical University General Hospital
Ages 18–80
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 2006; this study’s year is marked. 3 started in 2015.
This study's enrollment of 741 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 154 across the 43 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
21 studies in Anemia by Kyntra Bio: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 21 studies in Anemia by Kyntra Bio, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 3, and was the 10th registered.
Kyntra Bio’s Anemia studies by the year they started, since 2006.
1 of the studies testing roxadustat in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing roxadustat in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 21 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.
This study will consist of three study periods as follows:
Participants will be randomized in a 1:1 ratio to receive either roxadustat or epoetin alfa (active control) in an open-label manner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
Drug: Roxadustat
Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert \[USPI\] or Summary of Product Characteristics \[SmPC\]) or local SOC.
Drug: Epoetin Alfa
Epoetin alfa will be administered per dose and schedule specified in the arm.
Roxadustat will be administered per dose and schedule specified in the arm.
Also known as: FG-4592
US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.
Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52
Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol
Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.
Time frame: Baseline (Day 1, Week 0), Weeks 28 to 36
US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.
Time frame: Weeks 28 to 52
Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy
Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.
Time frame: Weeks 28 to 36
Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.
Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28
Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.
Time frame: Baseline (Day 1, Week 0), Weeks 18 to 24
Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52
Monthly iron use for each participant= Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.
Time frame: Weeks 28 to 52
Time to First RBC Transfusion
Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.
Time frame: Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa)
Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.
Time frame: Baseline (Day 1, Week 0), Weeks 20 to 28
Time to First Exacerbation of Hypertension During Weeks 28 to 52
An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.
Time frame: Weeks 28 to 52
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.
Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28
| Milestone | Roxadustat | Epoetin Alfa |
|---|---|---|
| Started | 370 | 371 |
| Received at least 1 dose of study drug | 370 | 370 |
| Completed | 127 | 183 |
| Not completed | 243 | 188 |
| Withdrew: Death | 70 | 62 |
| Withdrew: Withdrawal by subject | 41 | 29 |
| Withdrew: Kidney transplant | 31 | 39 |
| Withdrew: Physician decision | 30 | 15 |
| Withdrew: Adverse event | 27 | 9 |
| Withdrew: Lost to follow-up | 6 | 3 |
| Withdrew: Lack of efficacy | 6 | 1 |
| Withdrew: Protocol violation | 4 | 0 |
| Withdrew: Other than specified | 28 | 30 |
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.
| g/dL | Roxadustat | Epoetin Alfa |
|---|---|---|
| Baseline | 10.30 ± 0.661 | 10.31 ± 0.656 |
| Change at Weeks 28 to 52 | 0.39 ± 0.934 | -0.09 ± 0.838 |
Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.
| g/dL | Roxadustat | Epoetin Alfa |
|---|---|---|
| Baseline | 10.33 ± 0.639 | 10.35 ± 0.614 |
| Change at Weeks 28 to 36 | 0.54 ± 1.022 | -0.03 ± 0.897 |
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.
| percentage of participants | Roxadustat | Epoetin Alfa |
|---|---|---|
| US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy | 66.1 | 58.6 |
Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.
| percentage of participants | Roxadustat | Epoetin Alfa |
|---|---|---|
| Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy | 64.1 | 60.8 |
Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.
| mg/dL | Roxadustat | Epoetin Alfa |
|---|---|---|
| Baseline | 84.53 ± 34.009 | 84.45 ± 34.124 |
| Change at Weeks 12 to 28 | -13.70 ± 23.068 | 1.23 ± 22.389 |
Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.
| g/dL | Roxadustat | Epoetin Alfa |
|---|---|---|
| Baseline | 10.30 ± 0.616 | 10.24 ± 0.630 |
| Change at Weeks 18-24 | 0.61 ± 1.020 | -0.03 ± 0.940 |
Monthly iron use for each participant= Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.
| mg/PEM | Roxadustat | Epoetin Alfa |
|---|---|---|
| Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52 | 17.07 ± 53.375 | 37.02 ± 106.778 |
Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.
| weeks | Roxadustat | Epoetin Alfa |
|---|---|---|
| Time to First RBC Transfusion | NA (NA to NA) | NA (NA to NA) |
Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.
| millimeters of mercury (mmHg) | Roxadustat | Epoetin Alfa |
|---|---|---|
| Baseline | 101.41 ± 12.591 | 100.34 ± 12.350 |
| Change at Weeks 20 to 28 | 0.46 ± 10.933 | 0.04 ± 10.489 |
An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.
| weeks | Roxadustat | Epoetin Alfa |
|---|---|---|
| Time to First Exacerbation of Hypertension During Weeks 28 to 52 | NA (NA to NA) | NA (NA to NA) |
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.
| score on a scale | Roxadustat | Epoetin Alfa |
|---|---|---|
| Physical functioning subscore: Baseline | 38.55 ± 11.202 | 39.63 ± 11.368 |
| Physical functioning subscore: Change at Weeks 12 to 28 | -0.15 ± 7.443 | -0.20 ± 6.380 |
| Vitality subscore: Baseline | 51.65 ± 10.111 | 51.27 ± 9.841 |
| Vitality subscore: Change at Weeks 12 to 28 | -0.92 ± 7.007 | 0.30 ± 7.041 |
Collected over Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat | 70/370 (18.9%) | 242/370 (65.4%) | 286/370 (77.3%) |
| Epoetin Alfa | 62/370 (16.8%) | 248/370 (67%) | 292/370 (78.9%) |
| Event | Roxadustat | Epoetin Alfa |
|---|---|---|
| PneumoniaInfections and infestations | 30/370 | 39/370 |
| Acute myocardial infarctionCardiac disorders | 31/370 | 26/370 |
| Fluid overloadMetabolism and nutrition disorders | 24/370 | 27/370 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 15/370 | 26/370 |
| HyperkalaemiaMetabolism and nutrition disorders | 25/370 | 25/370 |
| Cardiac failure congestiveCardiac disorders | 23/370 | 23/370 |
| Cardiac arrestCardiac disorders | 20/370 | 23/370 |
| SepsisInfections and infestations | 18/370 | 23/370 |
| AnaemiaBlood and lymphatic system disorders | 16/370 | 20/370 |
| HypotensionVascular disorders | 18/370 | 19/370 |
| Event | Roxadustat | Epoetin Alfa |
|---|---|---|
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 53/370 | 71/370 |
| DiarrhoeaGastrointestinal disorders | 54/370 | 69/370 |
| CoughRespiratory, thoracic and mediastinal disorders | 49/370 | 69/370 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 56/370 | 64/370 |
| NauseaGastrointestinal disorders | 63/370 | 60/370 |
| VomitingGastrointestinal disorders | 60/370 | 55/370 |
| HypertensionVascular disorders | 59/370 | 44/370 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 49/370 | 58/370 |
| FallInjury, poisoning and procedural complications | 36/370 | 53/370 |
| ConstipationGastrointestinal disorders | 44/370 | 48/370 |
The intent to treat (ITT) population included all randomized participants.
| Age, Categorical(Participants) | Roxadustat | Epoetin Alfa | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 253 | 246 | 499 |
| >=65 years | 117 | 125 | 242 |
| Sex: Female, Male(Participants) | Roxadustat | Epoetin Alfa | Total |
|---|---|---|---|
| Female | 183 | 156 | 339 |
| Male | 187 | 215 | 402 |
| Ethnicity (NIH/OMB)(Participants) | Roxadustat | Epoetin Alfa | Total |
|---|---|---|---|
| Hispanic or Latino | 137 | 129 | 266 |
| Not Hispanic or Latino | 233 | 242 | 475 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Roxadustat | Epoetin Alfa | Total |
|---|---|---|---|
| Race — White | 165 | 184 | 349 |
| Race — Black/African American | 158 | 156 | 314 |
| Race — Asian | 21 | 15 | 36 |
| Race — American Indian/Alaskan Native | 10 | 7 | 17 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 |
| Race — Other | 15 | 6 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Sep 2018, 44 months.
Results were first posted in Oct 2021, 3 years 1 month after primary completion. A results delay was requested in Oct 2019.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 44 months is above that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat